Six major advances in the field of genetic testing - China Microbial Species Inquiry Network
1. MIT and Harvard University's “Multi-Genetic Risk Score†technology predicts the risk of five serious diseases Scientists at the Massachusetts Institute of Technology and the Broad Institute at Harvard University say they have developed a genome screening tool that predicts the mammary gland. The risk of cancer, type 2 diabetes, coronary artery disease, atrial fibrillation and inflammatory bowel disease. Identifying these high-risk groups helps to provide individualized preventive care. The Broad team worked with researchers at Massachusetts General Hospital (MGH) and Harvard Medical School to develop a method for assessing disease risk based on data from five existing conditions and genetic mutations. For each disease, they used an algorithm to combine all relevant genetic mutations into a single risk score. They then obtained genomic data from more than 400,000 people stored in the UK Biobank and used these algorithms to predict the risk of each person suffering from these diseases. The technology, called the "Multigene Risk Score," found that 8% of people in the UK's biological bank were three times more likely to have coronary artery disease than others. It also found that 1.5% of people in the biobank had a threefold increase in the risk of breast cancer. The research results were recently published in Nature Genetics.
2. GeneNews and LifeXTM collaborate to advance the clinical application of early liquid diagnostic techniques for "liquid biopsy"
On August 15th, GeneNews Limited, an innovative company in the field of liquid biopsy, announced a partnership with LifeXTM, based in Pittsburgh. The two companies will work together to advance a variety of proprietary early cancer diagnostic medical applications to improve patient compliance with cancer screening and to bridge the diagnostic gap in current cancer screening. GeneNews has tested and proven in thousands of patients that early detection of cancer can be achieved using a simple liquid biopsy. These tests are part of the AristotleTM platform, based on GeneNew's proprietary mRNA Sentinel Principle technology, which produces highly sensitive multi-gene detection tests for a variety of diseases. GeneNews is currently developing a genetic testing test to monitor 10 cancers in a single blood sample.
3. Natera and Fox Chase Cancer Center collaborate to study liquid biopsy to monitor renal cancer recurrence
Recently, Natera, the world's leading company in the field of cell-free DNA (cfDNA) detection, has teamed up with the famous Fox Chase Cancer Center in the United States to evaluate the effectiveness of the company's Circulating Tumor DNA (ctDNA) detection product, SignateraTM, in monitoring renal cancer recurrence. The study will analyze biological specimens collected and stored from 49 patients diagnosed with renal cancer, including the cancer recurrence group and the non-recurrent group after 3 years or longer. The study will assess whether Natera's Signatera products based on next-generation sequencing technology (NGS) can be used to distinguish between recurrent and non-recurrent kidney cancer cases. There are currently few data on ctDNA in renal cell carcinoma, and existing methods have limitations in sensitivity and specificity. This study will explore a new approach to diagnose renal cancer recurrence and monitor treatment response. By using Signatera analysis to determine the relationship between renal cancer genetic characteristics and prognosis (including recurrence), it is expected that early detection of cancer recurrence, assistance in treatment decisions, determination of treatment effects, and assessment of intervention needs are expected to improve patient care.
4. Seq2Know launches high cholesterol gene test
Recently, consumer genetic testing service company Seq2Know has released a familial hypercholesterolemia (FH) test product. This test included sequencing of four important genes responsible for FH (LDLR, APOB, PCSK9, LDLRAP1). FH is a hereditary high cholesterol disease that increases the risk of heart disease and stroke, the first and fifth leading causes of death in the United States. About one in six adults have high cholesterol. Although more than 30 million people may have FH, many are not aware of their risks. The FH Foundations' consensus statement on FH gene testing suggests that genetic testing as a diagnostic method can help prevent cardiovascular diseases associated with FH. Genetic testing is especially important for patients with persistent high cholesterol, early heart attack or a family history of high cholesterol or early onset heart disease.
5. IncellDx introduces liquid biopsy product - PD-L1 CTC test kit
IncellDx is an industry-leading single-cell cancer diagnostic company that recently introduced a complete pre-optimized kit for identifying, counting and quantifying PD-L1, an important tumor therapeutic target on circulating tumor cells (CTCs). As the company's first new reagent for cell liquid biopsy, BioINKTM accurately detects protein or mRNA expression in a single cell with high sensitivity and specificity. The company said that the ability to recognize and identify tumor cells at the individual cell level will help achieve early detection and treatment of cancer.
6. A review of the "Application of IDH Mutations in Brain Tumors" was published in Cancer Cell.
Recently, a review article on "The biological role and therapeutic potential of IDH mutations in cancer" was published in the authoritative international academic journal Cancer Cell. The paper was written by a visiting professor at Duke University, Dr. Yan Hai, co-founder and chief scientist of Genetron Health, and the Robert Tisch Brain Oncology Center at Princeton. This paper analyzes in detail the preclinical and clinical studies of IDH inhibitors in patients with glioma and acute myeloid leukemia (AML), and other possible alternative therapies and immunotherapy for patients with tumors carrying IDH1 / 2 mutations. Through extensive preclinical and clinical evidence, the development and validation of IDH mutation therapy strategies is important and will provide patients with future therapeutic benefits. The IDH1/TERT gene mutation detection kit developed by the pan-child study was approved by the CFDA in December 2017. It is suitable for the clinical detection of IDH1/R132H mutation in tumor tissues of glioma patients, and can provide an important reference for the pathological classification of glioma.
1. MIT and Harvard University's “Multi-Genetic Risk Score†technology predicts the risk of five serious diseases Scientists at the Massachusetts Institute of Technology and the Broad Institute at Harvard University say they have developed a genome screening tool that predicts the mammary gland. The risk of cancer, type 2 diabetes, coronary artery disease, atrial fibrillation and inflammatory bowel disease. Identifying these high-risk groups helps to provide individualized preventive care. The Broad team worked with researchers at Massachusetts General Hospital (MGH) and Harvard Medical School to develop a method for assessing disease risk based on data from five existing conditions and genetic mutations. For each disease, they used an algorithm to combine all relevant genetic mutations into a single risk score. They then obtained genomic data from more than 400,000 people stored in the UK Biobank and used these algorithms to predict the risk of each person suffering from these diseases. The technology, called the "Multigene Risk Score," found that 8% of people in the UK's biological bank were three times more likely to have coronary artery disease than others. It also found that 1.5% of people in the biobank had a threefold increase in the risk of breast cancer. The research results were recently published in Nature Genetics.
2. GeneNews and LifeXTM collaborate to advance the clinical application of early liquid diagnostic techniques for "liquid biopsy"
On August 15th, GeneNews Limited, an innovative company in the field of liquid biopsy, announced a partnership with LifeXTM, based in Pittsburgh. The two companies will work together to advance a variety of proprietary early cancer diagnostic medical applications to improve patient compliance with cancer screening and to bridge the diagnostic gap in current cancer screening. GeneNews has tested and proven in thousands of patients that early detection of cancer can be achieved using a simple liquid biopsy. These tests are part of the AristotleTM platform, based on GeneNew's proprietary mRNA Sentinel Principle technology, which produces highly sensitive multi-gene detection tests for a variety of diseases. GeneNews is currently developing a genetic testing test to monitor 10 cancers in a single blood sample.
3. Natera and Fox Chase Cancer Center collaborate to study liquid biopsy to monitor renal cancer recurrence
Recently, Natera, the world's leading company in the field of cell-free DNA (cfDNA) detection, has teamed up with the famous Fox Chase Cancer Center in the United States to evaluate the effectiveness of the company's Circulating Tumor DNA (ctDNA) detection product, SignateraTM, in monitoring renal cancer recurrence. The study will analyze biological specimens collected and stored from 49 patients diagnosed with renal cancer, including the cancer recurrence group and the non-recurrent group after 3 years or longer. The study will assess whether Natera's Signatera products based on next-generation sequencing technology (NGS) can be used to distinguish between recurrent and non-recurrent kidney cancer cases. There are currently few data on ctDNA in renal cell carcinoma, and existing methods have limitations in sensitivity and specificity. This study will explore a new approach to diagnose renal cancer recurrence and monitor treatment response. By using Signatera analysis to determine the relationship between renal cancer genetic characteristics and prognosis (including recurrence), it is expected that early detection of cancer recurrence, assistance in treatment decisions, determination of treatment effects, and assessment of intervention needs are expected to improve patient care.
4. Seq2Know launches high cholesterol gene test
Recently, consumer genetic testing service company Seq2Know has released a familial hypercholesterolemia (FH) test product. This test included sequencing of four important genes responsible for FH (LDLR, APOB, PCSK9, LDLRAP1). FH is a hereditary high cholesterol disease that increases the risk of heart disease and stroke, the first and fifth leading causes of death in the United States. About one in six adults have high cholesterol. Although more than 30 million people may have FH, many are not aware of their risks. The FH Foundations' consensus statement on FH gene testing suggests that genetic testing as a diagnostic method can help prevent cardiovascular diseases associated with FH. Genetic testing is especially important for patients with persistent high cholesterol, early heart attack or a family history of high cholesterol or early onset heart disease.
5. IncellDx introduces liquid biopsy product - PD-L1 CTC test kit
IncellDx is an industry-leading single-cell cancer diagnostic company that recently introduced a complete pre-optimized kit for identifying, counting and quantifying PD-L1, an important tumor therapeutic target on circulating tumor cells (CTCs). As the company's first new reagent for cell liquid biopsy, BioINKTM accurately detects protein or mRNA expression in a single cell with high sensitivity and specificity. The company said that the ability to recognize and identify tumor cells at the individual cell level will help achieve early detection and treatment of cancer.
6. A review of the "Application of IDH Mutations in Brain Tumors" was published in Cancer Cell.
Recently, a review article on "The biological role and therapeutic potential of IDH mutations in cancer" was published in the authoritative international academic journal Cancer Cell. The paper was written by a visiting professor at Duke University, Dr. Yan Hai, co-founder and chief scientist of Genetron Health, and the Robert Tisch Brain Oncology Center at Princeton. This paper analyzes in detail the preclinical and clinical studies of IDH inhibitors in patients with glioma and acute myeloid leukemia (AML), and other possible alternative therapies and immunotherapy for patients with tumors carrying IDH1 / 2 mutations. Through extensive preclinical and clinical evidence, the development and validation of IDH mutation therapy strategies is important and will provide patients with future therapeutic benefits. The IDH1/TERT gene mutation detection kit developed by the pan-child study was approved by the CFDA in December 2017. It is suitable for the clinical detection of IDH1/R132H mutation in tumor tissues of glioma patients, and can provide an important reference for the pathological classification of glioma.
Fresh Fruit refers to the edible fruits of plants with juicy and mainly sweet and sour tastes. Fruit not only contains rich vitamin nutrition, and can promote digestion. AGOLYN offers a variety of fruits such as Fresh apples, Fuji apples, kiwi, pears, lemons and so on .
Fresh Fruit,Fresh Apple,Kiwi Fruit, Fresh Lemon,Fresh Pears
Xi'an Gawen Biotechnology Co., Ltd , https://www.agolyn-bio.com